Research programme: cancer therapies - Compendia Bioscience/H3 Biomedicine
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Compendia Bioscience; H3 Biomedicine
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 08 Oct 2012 Compendia Bioscience has been acquired by Life Technologies Corporation
- 14 Feb 2012 Early research in Cancer in USA (unspecified route)